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Abstract

Literature Review

• The peer review literature compared the effectiveness of treating
allergic rhinitis (AR) with subcutaneous immunotherapy (SCIT)
versus sublingual immunotherapy (SLIT) for allergen-induced
rhinoconjunctivitis.

Pathophysiology of AR and the mechanism of action of SLIT
and SCIT

• The findings showed that there is no clear evidence of
effectiveness between SCIT and SLIT for reducing AR
symptoms. SLIT has been associated with cost savings with
comparison to SCIT.
• The findings indicated that SLIT may be the preferred route for
immunotherapy because of its convenience, comparable
efficacy, safety and cost.

Introduction
• The purpose of this review was to determine if SLIT was more
effective in treating IgE mediated grass-pollen induced
rhinoconjunctivitis than traditional SCIT.

• AR caused by seasonal grass pollen exposure is characterized
by rhinorrhea, sneezing and nasal pruritus, nasal congestion,
and includes ocular symptoms such as red/burning and
itchy/watery eyes.
• AR is most commonly treated with intranasal corticosteroids
and oral antihistamines. For poor control in moderate to severe
AR with oral antihistamines and intranasal corticosteroids,
immunotherapy should be considered.
• Both SCIT and SLIT increase allergen tolerance via similar
immune mechanisms, with reorientation of allergen-specific
CD4+ T-cell responses from a T helper 2 (Th2) to Th1 and
regulatory T-cell profiles. Allergen exposure modifies serum
levels of allergen specific IgE and IgG.

• The review of literature examined research comparing treatment
outcomes of SLIT to SCIT in individuals with IgE mediated
grass-pollen induced rhinoconjunctivitis.
• This information will enable one to compare treatment
outcomes between the two therapies, best delivery method,
safety and cost.

Cost effectiveness of SCIT and SLIT
Cost per patient for first
year of therapy

Cost per patient
for years 2 and 3
of therapy

Oralair

$1,003

$1,983

SCIT year round

$3,474

$2,852

SCIT Seasonal

$1,951

$3,867

Grazax

$2,171

$4,327

Safety of SCIT and SLIT
• Rate of one fatality per 2-2.5 million SCIT injections and one
case of anaphylaxis per 33,300 injections or per 4160 treatment
years (on the basis of eight injections per year). An estimated 1
billion doses of SLIT products (regardless or formulation-drops,
tablets, etc.) have been taken by patients since 2000. Eleven
cases of SLIT-induced anaphylaxis equate to around one case
per 100 million SLIT administrations or per 526,000 treatment
years.

Applicability to Clinical Practice
• Allergy patients most often present to primary care as a point of
first contact.
• Primary care providers (PCPs) should have the knowledge base
on how to select the appropriate treatment for a patient’s illness
and should be trained to make a comprehensive assessment and to
recognize treatment failure.
• PCPs interested in treating AR with allergen immunotherapy
should be trained in detection and management of side effects,
including systemic and local reactions.
• The PCP should be able to administer immunotherapy under the
mentorship of a trained allergist and maintain regular liaisons with
the allergist. In collaboration with the allergist, the PCP would be
able to jointly decide when to discontinue the therapy.
• The decision on whether to start the patient on allergy
immunotherapy should be made by an allergist.
• SLIT is viewed as more convenient for the patient because they
are able to take the tablet daily at home and does not require an
office visit. SCIT however, requires a weekly or monthly office
visit and requires the patient to wait 30 minutes after they
received their injection. As with any medication that is to be taken
at home; there is a risk of non-compliance by the patient.
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Statement of Problem
• AR is a common problem affecting between 30-40% of adults
and children.
• Uncontrolled AR is one of the most common reasons to visit a
healthcare provider.
• In the U.S., AR is responsible for 3.5 million lost workdays and
two million lost school days every year.
• If there is an effective prevention of AR there can be major
socio-economic benefits.

Research Questions
• In people with IgE mediated grass-pollen induced
rhinoconjunctivitis, does SLIT have better treatment outcomes
than traditional SCIT?

• In people with IgE mediated grass-pollen induced
rhinoconjunctivitis, what are the risks and costs associated with
SCIT and SLIT?

•

Comparison in effectiveness of SLIT to SCIT in AR
• Aasbjerg et al., examined the immunological comparison of
allergen SLIT and SCIT against grass allergy over 15 months.
The authors concluded 15 months of treatment was not
sufficient time to completely eradicate the differences in SLIT
tablet treatment and SCIT.
• A systematic review and meta-analysis was performed by
Dranitsaris & Ellis, evaluating Oralair, Grazax and SCIT. There
was a total of 20 placebo-controlled trial that met the inclusion
criteria. It was found that Oralair reduced the symptoms of AR
by approximately 0.47 units (p <0.001 on a validated symptom
scale relative to placebo). For comparison, Grazax and SCIT
had pooled reductions of 0.34 and 0.30, respectively.
• Dretzke et al., conducted a systematic review of effectiveness of
SCIT and SLIT versus placebo. A total of 17 placebo-controlled
RCTs for SCIT and 11 SLIT were utilized in the systematic
review. Only one randomized, double-blinded study (n=71) of
SLIT versus SCIT was identified during the search. No study
reported significant differences between SCIT and SLIT

Discussion
• Currently the mainstay of immunotherapy for AR is SCIT. The
long-term effect SCIT has on AR is well established. SLIT is a
newer concept and has been developed as a more convenient
form of immunotherapy.
• Dranitsaris and Ellis concluded from their systematic reviews of
double-blinded placebo controlled randomized trials evaluating
Oralair, Grazax and SCIT in patients with grass-induced
seasonal allergic rhinitis, that the three interventions produced
comparable benefits with reducing AR symptoms. There was
not a study reported that showed significant differences between
SCIT and SLIT in reducing symptoms of AR.
• In a study by Aasbjerg et al., the authors concluded 15 months
of treatment was not sufficient time to completely eradicate the
differences in SLIT tablet treatment and SCIT
• SLIT appears to be better tolerated than SCIT and majority of
SLIT adverse events are local reactions and occur during the
beginning of treatment and resolve within a days or weeks
without any medical intervention.
• Dranitsaris and Ellis recommended the use of Oralair for
immunotherapy because of its cost savings and similar efficacy
against SCIT and Grazax.
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